Overview

Exploratory Study on the Safety, Tolerability, and Pharmacodynamics of IMB-1018972 in Subjects With Angina Due to Obstructive Coronary Artery Disease (IMPROVE-Ischemia)

Status:
Recruiting

Trial end date:
2022-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety and tolerability of IMB-1018972 in subjects with obstructive CAD and inducible ischemia.

Phase:

Phase 2

Details

Lead Sponsor:

Imbria Pharmaceuticals, Inc.